Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.48 |
| ▸ | SPHK1 | Q9NYA1 | 4/20 | 0.46 |
| ▸ | CASR | P41180 | 1/20 | 0.46 |
| ▸ | FAAH | O00519 | 2/20 | 0.45 |
| ▸ | NPBWR1 | P48145 | 2/20 | 0.44 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.44 |
| ▸ | GBA1 | P04062 | 1/20 | 0.43 |
| ▸ | SPHK2 | Q9NRA0 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | CASP3 | P42574 | 1/20 | 0.39 |
| ▸ | CASP7 | P55210 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21157725 | 1.00 | HRH3 (0.48) | HRH3SPHK1CASRFAAHNPBWR1 | |
| SCHEMBL13527053 | 0.87 | HRH3 (0.53) | HRH3SPHK1CASRFAAHNPBWR1 | |
| SCHEMBL13527049 | 0.87 | HRH3 (0.53) | HRH3SPHK1CASRFAAHNPBWR1 | |
| SCHEMBL13527218 | 0.83 | HRH3 (0.54) | HRH3SPHK1CASRFAAHNPBWR1 | |
| SCHEMBL13527255 | 0.83 | HRH3 (0.54) | HRH3SPHK1CASRFAAHNPBWR1 | |
| SCHEMBL15060933 | 0.83 | HRH3 (0.56) | HRH3SPHK1FAAHNPBWR1MCHR1 | |
| SCHEMBL15060905 | 0.83 | HRH3 (0.56) | HRH3SPHK1FAAHNPBWR1MCHR1 | |
| SCHEMBL13480868 | 0.78 | GBA1 (0.60) | HRH3SPHK1FAAHNPBWR1MCHR1 | |
| SCHEMBL3563639 | 0.75 | HRH3 (0.53) | HRH3SPHK1CASRNPBWR1MCHR1 | |
| SCHEMBL27729943 | 0.74 | GBA1 (0.58) | HRH3SPHK1FAAHNPBWR1MCHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190211046-A1 | TRIAZOLE COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | BioVersys AG (CH) | 2019-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190211046-A1 | TRIAZOLE COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | PROKR1, ARG1, ARG2 | HRH3 140/4885SPHK1 2153/4885CASR 4777/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.